Uracil/Tegafur Plus Oral Calcium Folinate in Advanced Breast Cancer

OncologyONCOLOGY Vol 13 No 7
Volume 13
Issue 7

Uracil and tegafur (in a molar ratio of 4:1 [UFT]) has proven activity against breast cancer and is delivered in an easy-to-administer oral formulation. Orzel, which combines UFT with the oral biomodulator, calcium folinate, may

ABSTRACT: Uracil and tegafur (in a molar ratio of 4:1 [UFT]) has proven activity against breast cancer and is delivered in an easy-to-administer oral formulation. Orzel, which combines UFT with the oral biomodulator, calcium folinate, may provide even greater antitumor efficacy against breast cancer. Here, we describe the preliminary results of this phase II trial investigating the feasibility of 250 mg/m²/day of UFT plus 45 mg/day of oral calcium folinate administered to highly pretreated patients with advanced breast cancer. The results indicate a highly tolerable regimen and an overall response rate of 27.8% in a group of poor-prognosis patients. These findings warrant continued investigation. [ONCOLOGY 7(Suppl 3):96-97, 1999]


The overall prognosis for patients with advanced breast cancer who failed a first chemotherapy attempt remains poor. Currently, management with various combination-drug regimens seems to be primarily palliative, producing objective response rates of 20% to 40%. However, these regimens rarely cure and are associated with considerable toxicity.

UFT, an antineoplastic agent containing uracil plus tegafur in a molar ratio of 4:1, has demonstrated activity against colorectal, head and neck, and breast cancers in previous studies.[1-3] In breast cancer, response rates have ranged from 24% to 39%. This notable single-agent activity has resulted in escalation of research into its potential as therapy for breast cancer. UFT plus oral calcium folinate (Orzel) as a biomodulator possesses activity similar to that of intravenous 5-fluorouracil (5-FU) plus calcium folinate, with the additional advantage of oral delivery.[3] Based on this promising background, we designed a phase II protocol to evaluate the feasibility of using UFT plus oral calcium folinate to treat extensively pretreated patients with advanced breast cancer.[4-8]

Patients and Methods

Between June 1997 and April 1998, 24 patients were entered in this phase II tolerability study; only 18 patients were evaluable. Each patient had been previously treated for advanced breast cancer with chemotherapy or hormonal therapy. Prior regimens were based on the anthracyclines, paclitaxel (Taxol), vinorelbine (Navelbine), cyclophosphamide (Cytoxan), methotrexate, mitoxantrone (Novantrone), mitomycin-C (Mutamycin), 5-FU, tamoxifen (Nolvadex), and aminoglutethimide (Cytadren). The patient median age was 62 years (range, 46 to 75 years); Eastern Cooperative Oncology Group (ECOG) performance status was as follows: 0 in two patients; 1 in 14 patients, and 2 in eight patients (Table 1).

Patients were treated with UFT plus oral calcium folinate according to the following schema: 300 mg/m²/day of oral UFT plus 45 mg/day of oral calcium folinate administered every 12 hours for 28 days in cycles repeated every 35 days. Treatment history included UFT plus oral calcium folinate as second-line treatment for three patients (12.5%), as third-line treatment for 10 patients (41.7%), as fourth-line treatment for seven patients (29.2%), and as fifth-line treatment for four patients (16.7%).



A total of 63 cycles have been administered for a mean of three cycles (range, one to 10 cycles) per patient. Based on this follow-up, we have observed one complete response (5.6%) occurring in soft tissue sites, and four partial responses (22.2%). The overall response rate (complete response + partial response) was 27.8%. Responses were noted in soft tissue, lung, and bone. Disease was stable in eight patients (44.4%), and progressed in five patients (27.8%).

Compliance to treatment protocol was evaluated by means of a patient-completed drug-intake log. Based on these documents, compliance with the prescribed drug regimen appears to be reliable.


The toxicity of this regimen was generally mild to moderate (Table 2). Only one patient (5.56%) experienced grade 3 diarrhea during the first drug treatment cycle, which did not recur after the UFT dose was reduced to 250 mg/m²/day. Two patients presented with grade 2 diarrhea (11.11%) and four patients with grade 1 diarrhea (22.22%). Other observed toxicities included grade 2 abdominal pain in one patient (5.56%), grade 2 mucositis in two patients (11.11%), and grade 2 leukopenia in one patient (5.56%).

No patient required a treatment delay or withdrawal due to intolerance.


Based on our early results, oral administration of UFT plus oral calcium folinate appears to be easily administered and associated with low toxicity. In this study, a UFT plus oral calcium folinate regimen provided therapeutic benefit, accompanied by a good quality-of-life profile. This study continues to recruit patients. The final analysis will determine whether these results are borne out among a larger body of patients over a longer period of observation.


1. Feliu J, Gonzalez Baron M, Zamora P, et al: Experience of Oncopaz Cooperative Group with oral fluoropyrimidines in tumors of the stomach, lung, head and neck, and breast. Oncology 54(suppl 1):30-37, 1997.

2. Monserrat D, Diaz-Rubio E, Guillem V, et al: Phase II trial of UFT activity in pretreated breast cancer patients. Jpn J Clin Oncol 23:363-365, 1993.

3. Pazdur R, Lassere Y, Rhodes V, et al: Phase II trials of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 11:2296-2300, 1994.

4. Villalon A, De Guzman L, Samson M, et al: A comparative, randomized trial of UFT and 5-fluorouracil in combination with cyclophosphamide and doxorubicin in the treatment of advanced breast cancer patients at the Philippines General Hospital. Oncology 54(suppl 1):2-6, 1997.

5. Taguchi T: Clinical application of biochemical modulation in cancer chemotherapy: Biochemical modulation for 5-FU. Oncology 54(suppl 1):12-18, 1997.

6. Ansfield FJ, Ramirez G, Mackman S, et al: A 10-year study of 5-fluorouracil in disseminated breast cancer with clinical results and survival times. Cancer Res 29:1062-1066, 1969.

7. Haskell CM, Giulano AE, Thompson RW, et al: Breast cancer, in Haskell CM (ed): Cancer Treatment, 2nd ed, pp 137-180. Philadelphia, WB Saunders, 1985.

8. Itoh S, Kowishi Y, Harauchi D, et al: Clinical trial of UFT against disseminated breast cancer. Gan To Kagaku Ryoho 11:2381-2385, 1984.

Related Videos
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
Related Content